New Delhi: Glenmark Pharmaceuticals today said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19. The Mumbai-based drug firm had on Friday received manufacturing and marketing approval from the Drugs Controller General of India (DCGI). FabiFlu is the first oral Favipiravir-approved medication for…